High-dose megestrol acetate. A possible treatment for cachexia
- 6 March 1987
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA
- Vol. 257 (9) , 1195-1198
- https://doi.org/10.1001/jama.257.9.1195
Abstract
Weight loss and anorexia are significant complications of a variety of disorders and add morbidity to the underlying process. We observed marked weight gain (median 5.1 kg; range, 0.9 to 20.1 kg) and appetite enhancement in 27 of the 28 patients with breast cancer receiving treatment consisting of high doses of oral megestrol acetate (480 to 1600 mg/d). Weight gain occurred regardless of pretreatment weight, extent of metastases, or response to therapy. Our results suggest a possible role for megestrol acetate in reversing anorexia and weight loss, thereby improving the quality of life of patients with cachexia. Further research is needed to establish the mechanism of weight gain and potential clinical applications.This publication has 8 references indexed in Scilit:
- A Macrophage Factor Inhibits Adipocyte Gene Expression: An in Vitro Model of CachexiaScience, 1985
- Purification of cachectin, a lipoprotein lipase-suppressing hormone secreted by endotoxin-induced RAW 264.7 cells.The Journal of Experimental Medicine, 1985
- Megestrol acetate therapy for advanced breast cancer.Journal of Clinical Oncology, 1985
- Energy Expenditure in Malnourished Cancer PatientsAnnals of Surgery, 1983
- A controlled, prospective, randomized trial evaluating the metabolic effects of enteral and parenteral nutrition in the cancer patientCancer, 1982
- Treatment of advanced breast cancer with megestrol acetate after therapy with tamoxifenCancer, 1982
- Progestin therapy in advanced breast cancer: Megestrol acetate—an evaluation of 160 treated casesCancer, 1980
- Protein-calorie undernutrition in hospitalized cancer patientsThe American Journal of Medicine, 1980